LMAT Stock Overview
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
LeMaitre Vascular, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$62.77 |
| 52 Week High | US$74.64 |
| 52 Week Low | US$44.27 |
| Beta | 0.88 |
| 1 Month Change | -5.52% |
| 3 Month Change | 9.24% |
| 1 Year Change | 14.38% |
| 3 Year Change | 18.41% |
| 5 Year Change | 117.35% |
| Change since IPO | 912.42% |
Recent News & Updates
Recent updates
Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?
Apr 04
Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Feb 29What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?
Jan 19Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture
Oct 27Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
Oct 11Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?
Aug 30The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence
Jul 06Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?
May 20Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?
Mar 12Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?
Oct 23Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Oct 05LeMaitre Vascular (NASDAQ:LMAT) Could Be Struggling To Allocate Capital
Sep 13LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers
Sep 08LeMaitre Vascular goes ex dividend tomorrow
Aug 23LeMaitre Vascular: 16% Return Objective From Idiosyncratic Risk Premia
Jun 24What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?
Jun 15Are Investors Undervaluing LeMaitre Vascular, Inc. (NASDAQ:LMAT) By 40%?
May 06LeMaitre Vascular: Steady As She Goes
Apr 07With EPS Growth And More, LeMaitre Vascular (NASDAQ:LMAT) Is Interesting
Apr 02LeMaitre Vascular (NASDAQ:LMAT) Will Want To Turn Around Its Return Trends
Mar 15LeMaitre Vascular (NASDAQ:LMAT) Is Increasing Its Dividend To US$0.13
Mar 01Shareholder Returns
| LMAT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.1% | -2.9% | -3.2% |
| 1Y | 14.4% | -3.7% | 19.3% |
Return vs Industry: LMAT exceeded the US Medical Equipment industry which returned -3.7% over the past year.
Return vs Market: LMAT underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| LMAT volatility | |
|---|---|
| LMAT Average Weekly Movement | 5.7% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LMAT has not had significant price volatility in the past 3 months.
Volatility Over Time: LMAT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 622 | George LeMaitre | www.lemaitre.com |
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries.
LeMaitre Vascular, Inc. Fundamentals Summary
| LMAT fundamental statistics | |
|---|---|
| Market cap | US$1.41b |
| Earnings (TTM) | US$30.11m |
| Revenue (TTM) | US$193.48m |
46.8x
P/E Ratio7.3x
P/S RatioIs LMAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LMAT income statement (TTM) | |
|---|---|
| Revenue | US$193.48m |
| Cost of Revenue | US$66.44m |
| Gross Profit | US$127.05m |
| Other Expenses | US$96.94m |
| Earnings | US$30.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 1.34 |
| Gross Margin | 65.66% |
| Net Profit Margin | 15.56% |
| Debt/Equity Ratio | 0% |
How did LMAT perform over the long term?
See historical performance and comparison